Literature DB >> 34534012

Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.

Faezeh Maghsood1, Danesh Hassani1, Vahid Salimi2, Gholam Ali Kardar3, Jalal Khoshnoodi1, Abbas Ghaderi4, Seyyed Reza Raeeskarami5, Abdorrahman Rostamian6, Monireh Sadat Seyyedsalehi7, Raoufeh Ahmadi Fesharaki1, Mahmood Jeddi-Tehrani8, Amir-Hassan Zarnani1, Mohammad Mehdi Amiri1, Fazel Shokri1.   

Abstract

The coronavirus infectious disease 2019 (COVID-19), which is initiated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed critical challenges to global health. Understanding the kinetic of SARS-CoV-2-specific IgM and IgG responses in different subsets of COVID-19 patients is crucial to get insight into the humoral immune response elicited against the virus. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and receptor-binding domain (RBD) of spike protein in two groups of recovered and deceased COVID-19 patients. The levels of IgM and IgG specific to N and RBD proteins were detected by ELISA. N- and RBD-specific IgM was higher in deceased patients in comparison with recovered patients, while there was no significant difference in N- and RBD-specific IgG between the two groups. A significant correlation was observed between IgG and IgM titers against RBD and N, in both groups of patients. These results argue against impaired antibody response in deceased COVID-19 patients.

Entities:  

Keywords:  COVID-19; RBD; SARS-CoV-2; antibody; nucleocapsid

Mesh:

Substances:

Year:  2021        PMID: 34534012     DOI: 10.1089/vim.2021.0061

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  1 in total

Review 1.  Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.

Authors:  Somayeh Ghotloo; Faezeh Maghsood; Forough Golsaz-Shirazi; Mohammad Mehdi Amiri; Christiane Moog; Fazel Shokri
Journal:  Rev Med Virol       Date:  2022-04-08       Impact factor: 11.043

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.